ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2654

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis

Ellen Romich1, Alexis Ogdie2, Alisa Stephens Shields2, Peter Merkel2, Jessica Alvey3, Shervin Assassi4, Elana Bernstein5, Sonali Bracken6, Flavia Castelino7, Lorinda Chung8, Luke Evnin9, Tracy Frech10, Jessica Gordon11, Faye Hant12, Monica Harding13, Laura Hummers14, Dinesh Khanna15, Kimberly Lakin11, Dorota Lebiedz-Odrobina13, Yiming Luo5, Ashima Makol16, Maureen Mayes17, Zsuzsanna McMahan18, Jerry Molitor19, Duncan Moore20, Carrie Richardson21, Ami Shah14, Ankoor Shah22, Brian Skaug23, Virginia Steen24, John VanBuren13, Elizabeth Volkmann25, Carleigh Zahn15 and Nora Sandorfi2, 1University of Pennsylvania, Media, PA, 2University of Pennsylvania, Philadelphia, PA, 3Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, 4Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, 5Columbia University, New York, NY, 6Duke University Medical Center, Durham, NC, USA, Apex, NC, 7Massachusetts General Hospital, Boston, MA, 8Stanford University, Stanford, CA, 9Scleroderma Research Foundation, San Francisco, CA, 10Vanderbilt University Medical Center, Nashville, TN, 11Hospital for Special Surgery, New York, NY, 12Medical University of South Carolina, Charleston, SC, 13University of Utah, Salt Lake City, UT, 14Johns Hopkins Rheumatology, Baltimore, MD, 15University of Michigan, Ann Arbor, MI, 16Mayo Clinic, Rochester, MN, 17UT Health Houston Division of Rheumatology, Houston, TX, 18UT Health Houston, Houston, TX, 19University of Minnesota, Minneapolis, MN, 20Northwestern Memorial Hospital, Chicago, IL, 21Northwestern University, Chicago, IL, 22Duke University, Durham, NC, 23UTHealth Houston Division of Rheumatology, Houston, TX, 24Georgetown University School of Medicine, Washington, DC, 25Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA

Meeting: ACR Convergence 2025

Keywords: Disease Activity, Outcome measures, Patient reported outcomes, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 29, 2025

Title: Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)

Session Type: Abstract Session

Session Time: 10:15AM-10:30AM

Background/Purpose: To determine the frequency and extent of discordance between patient and physician global assessments of disease in early systemic sclerosis and identify factors associated with discordance.

Methods: Adult patients with early systemic sclerosis from the COllaborative National QUality and Efficacy Registry (CONQUER) were included. Global disease assessments by patients and physicians (0-10, higher is worse, 7-day recall), clinical evaluations, and patient-reported outcomes were collected at enrollment and every 6 months. Score concordance was defined as patient and physician global scores within 1 point, and discordance as a difference of ≥ 2 points, creating 3 categories: concordance, patient scores worse, and physician scores worse. The frequency of discordance and correlation between global assessments were determined for the enrollment visit, and factors associated with discordance were assessed using multivariable mixed-effects proportional odds regression with concordance as the reference category.

Results: 956 patients (83% female, 33% limited cutaneous disease, 19% with disease duration < 1 year) with both global assessments available were included (Table 1). The correlation between patient and physician global assessments was weak (Pearson’s r=0.28) (Figure 1). Discordance between global assessments was present in 510 (53%) of patients (35% patient score worse; 19% physician score worse)(Figure 2). In the multivariable model, compared to score concordance, physicians tended to report global scores worse than patient scores when there was a higher modified Rodnan skin score (mRSS)(odds ratio (OR), [95% confidence interval (CI)]: 1.03 [1.01, 1.05]), worse New York Heart Association (NYHA) functional Class (Class II OR 1.78 [1.20, 2.65]; Class III/IV: 2.83 [1.07, 7.46]), and higher PROMIS Pain Interference (OR 1.03, [1.00, 1.05]), while higher diffusing capacity of the lung for carbon monoxide (DLCO) %-predicted (OR 0.94 [0.90, 0.98]) was associated with lower likelihood of discordance with physician scores worse. Patients tended to report global scores worse than physician scores when there was higher overall pain/discomfort (OR 1.29 [1.18, 1.42]), while decreased likelihood of discordance with the patient scores worse was observed for limited vs. diffuse cutaneous subtype (OR 0.45 [0.28, 0.71]), higher mRSS (OR 0.97 [0.95, 0.99]), and worse NYHA functional Class (Class III/IV OR 0.29 [0.13, 0.66]).

Conclusion: Discordance between global assessments is present in over half of cases in systemic sclerosis, with patients tending to rate their condition worse compared to their physician’s rating. Discordance in which physician scores are worse is associated with disease characteristics and measures of severity, while discordance in which patient scores are worse is associated with increased pain and lower likelihood of severe manifestations. Physicians may underestimate disease impact when disease manifestations are less severe. These results highlight differing perceptions of disease severity and emphasize the need for comprehensive approaches to symptom management and measurement of disease burden in this complex disease.

Supporting image 1

Supporting image 2Figure 1. Scatterplot and distributions of patient and physician global assessments of overall disease activity in systemic sclerosis at enrollment visit.

The size of the blue circles represents the number of patients with each score combination. Points above the gray lines indicate discordance with the patient score worse, while points below the gray lines indicate discordance with the physician score worse. Points between the gray lines are concordant. Mean (standard deviation) global assessments at enrollment were 4.2 (2.6) and 3.5 (2.0) among patients and physicians, respectively. The distributions demonstrate that patients are more likely to utilize the full range of scores compared to physicians.

Supporting image 3Figure 2. Distribution of differences between patient and physician global assessment scores among patients with systemic sclerosis at enrollment visit.

Global assessment score concordance (+/- 1 point) was present in 47% of patient-physician assessments at the enrollment visit (blue). Discordance (≥ 2-point difference) was present in 53%. Patient global assessment scores were worse than the physician scores in 35% (green), while physician global assessment scores were worse than the patient scores in 19% (purple). Patient scores were more likely to show high discordance, with 15% of scores 4 or more points higher than the corresponding physician scores.


Disclosures: E. Romich: Lungpacer Medical, Inc., 11, Teva Pharmaceuticals, 12, Spouse employment; A. Ogdie: AbbVie, 2, 5, Amgen, 2, 5, 11, Bristol Myers Squibb, 2, 5, Celgene, 2, 5, CorEvitas, LLC, 2, 5, Eli Lilly, 2, 5, Forward Databank, 5, Gilead, 1, 2, Janssen, 2, 5, Kopa/Twill Health, 2, NIH/NIAMS, National Psoriasis Foundation, 5, Novartis, 2, 5, 11, Pfizer, 2, 5, 11, Rheumatology Research Foundation, 5, Spyre, 2, Takeda, 2, UCB, 2, 5, University of Pennsylvania, 5; A. Stephens Shields: None; P. Merkel: AbbVie, 2, 5, Alpine, 2, Amgen, 2, 5, ArGenx, 2, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb (BMS), 2, 5, CSL Behring, 2, Eicos, 5, Electra, 5, GlaxoSmithKlein (GSK), 2, 5, iCell, 2, Interius, 2, Kinevant, 2, Kyverna, 2, 11, Lifordi, 11, Metagenomia, 2, Neutrolis, 2, 5, 11, Novartis, 2, NS Pharma, 2, Otsuka, 2, Q32, 2, 11, Quell, 2, Regeneron, 2, Sanofi, 2, Sparrow, 2, 11, Takeda, 2, 5, UpToDate, 9, Vistera, 2; J. Alvey: None; S. Assassi: AbbVie, 2, AstraZeneca, 2, aTyr, 2, 5, Boehringer Ingelheim, 2, 5, 6, 12, Medical writing support provided by Fleishman Hillard, CSL Behring, 2, Janssen, 5, Merck, 2, Mitsubishi Tanabe, 2, PeerView Institute for Medical Education, 6, Scleroderma Research Foundation, 5, 6, Takeda, 2, TeneoFour, 2; E. Bernstein: AstraZeneca, 5, aTyr, 5, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 5, Cabaletta Bio, 5, Synthekine, 2; S. Bracken: None; F. Castelino: Boehringer-Ingelheim, 2, Genentech, 5, Horizon, 5, Mediar Therapeutics, 1, Takeda, 1; L. Chung: AbbVie/Abbott, 1, Boehringer-Ingelheim, 1, CRISPR Therpeutics, 2, Cure Ventures, 2, jade, 2, Kyverna, 6, Mediar, 1, 2; L. Evnin: None; T. Frech: None; J. Gordon: Cumberland, 5, Prometheus/Merck, 5; F. Hant: None; M. Harding: None; L. Hummers: AbbVie/Abbott, 1, AstraZeneca, 5, Biotest, 2, Boehringer-Ingelheim, 1, 5, Cumberland Pharmaceuticals, 5, GlaxoSmithKlein(GSK), 5, Horizon Pharma, 5, Merck/MSD, 5, Mitsubishi Tanabe, 5; D. Khanna: Argenx, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Novartis, 2, UCB, 2, Zura Bio, 2; K. Lakin: None; D. Lebiedz-Odrobina: None; Y. Luo: None; A. Makol: Amgen, 12, Site PI for Clinical trial, AstraZeneca, 12, Site PI for Clinical trial, Boehringer-Ingelheim, 1, 12, Site PI for Clinical trial, Sanofi Genzyme, 12, Site PI for Clinical trial; M. Mayes: Argenx, 2, AstraZeneca, 5, atyr, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 1, 5, h, 5, Novartis, 2, prometheus merck, 5; Z. McMahan: Aera Therapeutics, 2, Allogene, 2, Boehringer-Ingelheim, 2, guidepoint, 2; J. Molitor: None; D. Moore: AstraZeneca, 5; C. Richardson: Cabaletta Bio, 2; A. Shah: None; A. Shah: Adtium Bio, 2, Cabaletta Bio, 5, Horizon Therapeuatics, 5, Mitsubishi, 2; B. Skaug: None; V. Steen: None; J. VanBuren: None; E. Volkmann: AbbVie, 2, Boehringer-Ingelheim, 2, 5, 6, 12, Medical writing support provided by Fleishman Hillard, Bristol-Myers Squibb(BMS), 2, GlaxoSmithKleine, 2, 5, Horizon, 5, Kadmon, 5, Prometheus, 5, The National Heart, Lung and Blood Institute, 5; C. Zahn: None; N. Sandorfi: Bristol-Myers Squibb(BMS), 2, Immunovant, 2, Janssen, 2, Novartis, 1.

To cite this abstract in AMA style:

Romich E, Ogdie A, Stephens Shields A, Merkel P, Alvey J, Assassi S, Bernstein E, Bracken S, Castelino F, Chung L, Evnin L, Frech T, Gordon J, Hant F, Harding M, Hummers L, Khanna D, Lakin K, Lebiedz-Odrobina D, Luo Y, Makol A, Mayes M, McMahan Z, Molitor J, Moore D, Richardson C, Shah A, Shah A, Skaug B, Steen V, VanBuren J, Volkmann E, Zahn C, Sandorfi N. Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/discordance-between-patient-and-physician-global-assessments-in-early-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discordance-between-patient-and-physician-global-assessments-in-early-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology